Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mitomycin ophthalmic - Mobius Therapeutics

Drug Profile

Mitomycin ophthalmic - Mobius Therapeutics

Alternative Names: Mitomycin-c ophthalmic solution - Mobius Therapeutics; Mitosol

Latest Information Update: 09 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mobius Therapeutics
  • Class Antineoplastics; Aziridines; Carbamates; Cytostatic antibiotics; Glucosidases; Indoles; Recombinant proteins; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Corneal disorders; Recurrent pterygium; Glaucoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glaucoma
  • Preregistration Corneal disorders; Recurrent pterygium

Most Recent Events

  • 09 Oct 2018 Mitomycin ophthalmic (Mitosol®) is still in preregistration phase and awaiting regulatory approval from the USFDA for Recurrent pterygium
  • 31 Oct 2017 Mitomycin ophthalmic receives expanded Orphan Drug status for all Glaucoma surgery in USA
  • 09 Sep 2015 Mitomycin opthalmic is still awaiting approval for corneal disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top